Filing Summary
Registrant: MedTech Acquisition Corporation, not Trisalus Life Sciences, Inc. The filing is a Form 8-K reporting an event dated June 26, 2023; it was signed and dated June 30, 2023. The registrant was a Nasdaq-listed special purpose acquisition company.
Material Transaction
- On June 26, 2023, the company issued 6,249,999 shares of Class A common stock to MedTech Acquisition Sponsor LLC.
- The shares were issued upon conversion of an equal number of Class B common shares held by the Sponsor.
- The converted shares represented approximately 84.5% of the company’s total issued and outstanding Class A shares after the conversion.
- The issuance was claimed to be exempt from registration under Section 3(a)(9) of the Securities Act.
Restrictions and Governance Provisions
The converted Class A shares remained subject to restrictions that previously applied to the Class B shares, including transfer restrictions, waiver of redemption rights, and an obligation to vote in favor of the company’s initial business combination, as described in the company’s IPO prospectus.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or operating forecasts. It is limited to reporting the equity conversion and related exemption from registration.
Investor Verification Items
- Confirm that the filing pertains to MedTech Acquisition Corporation rather than Trisalus Life Sciences, Inc.
- Verify the final number of Class A shares outstanding following the conversion and the resulting ownership percentage.
- Review the IPO prospectus for the detailed transfer restrictions, redemption waivers, and voting obligations attached to the converted shares.
- Assess how the Sponsor’s approximately 84.5% position may affect approval of a future business combination and public-stockholder voting influence.